Frailty scoring in the management of people with skin cancer: a critically appraised topic

Clicks: 28
ID: 327812
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #38 of 243 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 243 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Skin cancer incidence is rising in the UK, and with an increasingly aging population, so is frailty. Frailty scoring is not routinely utilised in skin cancer multi-disciplinary team decisions but may have the potential to enhance and personalise clinical management. The aim of this narrative review is to evaluate the literature on clinical tools used to assess frailty, guide management of people with skin cancer (melanoma and keratinocyte cancer) and identify the best frailty score to be used in skin cancer multi-disciplinary team management decisions in the UK. A literature search was conducted using MEDLINE and the results were screened for relevance to the clinical question. From the literature, we identified 12 different scoring tools studied in the management of skin cancer, across 15 papers, which we sub-categorised into 'comorbidity' and 'frailty' assessment tools. Of these, the Geriatric-8, Charlson Comorbidity Index and Adult Comorbidity Evaluation-27 were identified to be the most effective at identifying and stratifying frailty. However, the Rockwood Clinical Frailty Score is currently recommended by the British Geriatric Society and British Association of Dermatology. Notwithstanding the limitations of this critical appraisal (small cohort sizes, single-centre bias and overlapping or similar patient populations) we conclude that frailty scoring should be used in skin cancer multi-disciplinary teams so that patient related factors and tumour related factors are considered when managing skin cancer in older patients. Frailty scoring helps identify patients with limited life-expectancy and greater risk of complications, who may not benefit from 'gold-standard' treatments.
Reference Key
openalex_W7211954946 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Anna M Hughes, James Powell, Rachel Abbott
Are you one of these authors? Claim your profile
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag388
URL
https://doi.org/10.1093/ced/llag388
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.